Lipid lowering with thyroid hormone and thyromimetics

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 499-506

  Angelin, Bo ^a   Rudling, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cholesterol; hyperlipidemia; lipoprotein; liver; triglyceride

Indexed keywords

3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTEROL; EPROTIROME; EZETIMIBE; FAT; GC 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIOTHYRONINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MB 07811; PARATHYROID HORMONE DERIVATIVE; PLACEBO; SIMVASTATIN; SOBETIROME; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG BINDING; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATTY LIVER; HEART; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER; MEDICAL RESEARCH; MUSCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; BIOMIMETICS; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPID METABOLISM; MOLECULAR MIMICRY; ORGAN SPECIFICITY; RECEPTORS, LDL; THYROID GLAND; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; THYROID HORMONES;

ANIMALIA;

EID: 78650309921     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283402e9c     Document Type: Review

References (49)

1. Moreno M, de Lange P, Lombardi A, et al. Metabolic effects of thyroid hormone derivatives. Thyroid 2008; 18:239-253.
2. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007; 21:193-208.
3. Visser T. Biosynthesis, transport, metabolism, and actions of thyroid hormones. In: Wass JAH, editor. Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press; 2002. pp. 287-301.
4. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81:1097-1142.
5. Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol 2000; 62:439-466.
6. Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993; 14:184-193.
7. Araki O, Ying H, Zhu XG, et al. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol 2009; 23:308-315.
8. Gullberg H, Rudling M, Forrest D, et al. Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol Endocrinol 2000; 14:1739-1749.
9. Valadares NF, Polikarpov I, Garratt RC. Ligand induced interaction of thyroid hormone receptor beta with its coregulators. J Steroid Biochem Mol Biol 2008; 112:205-212.
10. Hashimoto K, Matsumoto S, Yamada M, et al. Liver X receptor-alpha gene expression is positively regulated by thyroid hormone. Endocrinology 2007; 148:4667-4675.
11. Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab 2010; 21:166-173.
12. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31:139-170.
13. Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes 2010. [Epub ahead of print]
14. Gullberg H, Rudling M, Salto C, et al. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002; 16:1767-1777.
15. Nikkila EA, Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1972; 51:2103-2114.
16. Packard CJ, Shepherd J, Lindsay GM, et al. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab 1993; 76:1209-1216.
17. Lopez D, Abisambra Socarras JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta 2007; 1771:1216-1225.
18. Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 1990; 172:1150-1156.
19. Tancevski I, Demetz E, Eller P, et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One 2010; 5:e8722.
20. Tancevski I, Wehinger A, Demetz E, et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res 2009; 50:938-944.
21. Thompson GR, Soutar AK, Spengel FA, et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981; 78:2591-2595.
22. Erion MD, Cable EE, Ito BR, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104:15490-15495.
23. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102:10297-10302.
24. Tan KC, Shiu SW, Kung AW. Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998; 83:2921-2924.
25. Tan KC, Shiu SW, Kung AW. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab 1998; 83:1 40-143.
26. Galman C, Bonde Y, Matasconi M, et al. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 2008; 134:1127-1136.
27. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipo-protein(a). Clin Chem 1993; 39:2466-2469.
28. Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004; 145:1656-1661.
29. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003; 100:10067-10072.
30. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906-916.
31. Prieur X, Huby T, Coste H, et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005; 280:27533-27543.
32. Adams AC, Astapova I, Fisher FM, et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. J Biol Chem 2010; 285:14078-14082.
33. Strisower B, Gofman JW, Galioni EF, et al. Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels. Lancet 1957; 272:120-123.
34. The Coronary Drug Project Research Group. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972; 220:996-1008.
35. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8:308-320.
36. Underwood AH, Emmett JC, Ellis D, et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986; 324:425-429.
37. HiranoT, Kagechika H. Thyromimetics: a review of recent reports and patents (2004-2009). Expert Opin Ther Pat 2010; 20:213-228.
38. Malm J, Grover GJ, Farnegardh M. Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor. Mini Rev Med Chem 2007; 7:79-86.
39. BoyerSH, Jiang H, Jacintho JD, et al. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 2008; 51:7075-7093.
40. Ito BR, Zhang BH, Cable EE, et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009; 156:454-465.
41. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8:169-174.
42. Bryzgalova G, Effendic S, Khan A, et al. Antiobesity, antidiabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008; 111:262-267.
43. Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49:407-417.
44. Perra A, Simbula G, Simbula M, et al. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22:2981-2989.
45. Smith SR, Lovejoy JC, Rood J, et al. The effects of triiodothyronine on bone metabolism in healthy ambulatory men. Thyroid 2003; 13:357-364.
46. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010; 95:1349-1354.
47. Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009; 119:3093-3100.
48. Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008; 105:663-667.
49. Angelin B. Therapy for lowering lipoprotein (a) levels. CurrOpin Lipidol 1997; 8:337-341.